Russia expects South Korea to ensure security at Winter Olympics — KremlinSport September 22, 13:13
Kremlin spokesman says no plans to deploy UN mission to Russian-Ukrainian borderRussian Politics & Diplomacy September 22, 13:04
Putin assesses Zapad-2017 military drillsMilitary & Defense September 22, 13:00
Press review: What Putin said behind closed doors and US changes tone on SyriaPress Review September 22, 13:00
Austria's top diplomat seeks to arrange Putin-Trump summit in ViennaWorld September 22, 12:53
Russian aircraft scrambled 14 times in a week to intercept foreign jets along bordersMilitary & Defense September 22, 12:26
Moscow expects up to one million football fans for 2018 FIFA World CupSport September 22, 12:09
Bolshoi Theater announces Nureyev ballet premiere in early DecemberSociety & Culture September 22, 12:00
Austrian opposition calls for accepting Crimea’s reunification with RussiaWorld September 22, 11:51
GENEVA, October 3. /TASS/. The Court of Arbitration for Sport (CAS) is set to announce a decision on the appeal of Russian tennis star Maria Sharapova, submitted in summer against her two-year ban, on Tuesday, October 4, the court said in its statement on Monday.
"Decision in the case of Maria Sharapova v. International Tennis Federation to be released at 3.00 pm (Swiss time) on 4 October 2016," the statement said.
On June 9, Sharapova filed an appeal with the CAS in Switzerland’s Lausanne against her two-year suspension, which was imposed on June 8 by the International Tennis Federation’s (ITF) Tribunal over anti-doping violations.
Due to the imposed ban world’s former No. 1 Sharapova had to miss the 2016 Summer Olympic Games, held in August in Brazil’s Rio de Janeiro.
In early March, Sharapova announced that her doping tests revealed the presence of performance enhancing drug meldonium in the body system. Following the announcement, former World’s No. 1 was provisionally suspended from all tennis-related activities.
The drug meldonium (mildronate) was included in the list of preparations banned by WADA from January 1, 2016. The presence of the meldonium substance in the athlete’s blood during and between competitions is a violation of anti-doping rules. The substance belongs to S4 class on the WADA blacklist (hormones and metabolic modulators).
WADA announced on April 13 that the concentration of less than one microgram of meldonium in the body system of an athlete, whose doping tests were conducted before March 1, was acceptable.